Article Per Year (5 Year)
p-Index From 2021 - 2026
0.562
P-Index
This Author published in this journals
All Journal CoMPHI Journal : Community Medicine and Public Health of Indonesia Journal Hang Tuah Medical Journal
Wijayaningrum, Lena
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Dentistry Health Professions Medicine & Pharmacology Nursing Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Karakteristik Pasien Stroke Di Klinik Rehabilitasi Medik Rspal Dr. Ramelan Surabaya Periode Januari – Juni 2024 Febrian, Amellia Ika; Jauhar, Tamam; Wijayaningrum, Lena; Tjahjono, Varidianto Yudo
CoMPHI Journal: Community Medicine and Public Health of Indonesia Journal Vol. 5 No. 3 (2025): Februari
Publisher : Perhimpunan Dokter Kedokteran Komunitas dan Kesehatan Masyarakat Indonesia (PDK3MI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37148/comphijournal.v5i3.271

Abstract

Stroke adalah kelainan neurologi yang menjadi faktor penyebab kematian terbanyak kedua di dunia. Penderita stroke umumnya berusia diatas 50 tahun dan banyak yang berasal dari negara berkembang. Stroke bisa terjadi karena banyak faktor, seperti penyakit penyerta, pola hidup buruk, lingkungan yang kurang sehat, dan kurangnya aktivitas fisik. Meskipun stroke banyak terjadi di usia lanjut, namun faktor risiko tersebut banyak didapatkan ketika usia muda yang dapat meningkatkan risiko stroke di usia mendatang. Penelitian ini bertujuan untuk mengetahui karakteristik pasien stroke di klinik Rehabilitasi Medik RSPAL dr. Ramelan Surabaya periode Januari – Juni 2024. Metode penelitian yang digunakan adalah deskriptif dengan pengambilan sampel menggunakan metode total sampling. Populasi penelitian adalah seluruh pasien stroke yang memiliki rekam medis lengkap. Data yang dilihat antara lain usia, jenis kelamin, penyakit penyerta berupa hipertensi dan diabetes mellitus. Berdasarkan data yang diperoleh dari rekam medis didapatkan 70 sampel dengan variabel penelitian hipertensi, diabetes mellitus, usia, dan jenis kelamin. Distribusi pasien stroke dengan faktor risiko hipertensi berjumlah 53 orang. Distribusi pasien stroke dengan faktor risiko diabetes mellitus berjumlah 24 orang. Distribusi pasien stroke dengan faktor usia mayoritas termasuk dalam usia ≥45 tahun sebanyak 66 orang. Distribusi pasien stroke dengan faktor risiko jenis kelamin mayoritas pada laki-laki sebanyak 47 orang. Kesimpulan penelitian ini yaitu faktor risiko yang mendominasi kejadian stroke pada pasien stroke di Klinik Rehabilitasi Medik RSPAL dr. Ramelan Surabaya periode Januari – Juni 2024 adalah memiliki hipertensi, berjenis kelamin laki-laki, dan berusia ≥45 tahun
Metaplasia Myelofibrosis WIJAYANINGRUM, LENA; I DEWA MADE WIDI HERSANA; I KETUT TIRKA NANDAKA
Hang Tuah Medical Journal Vol 23 No 1 (2025): Hang Tuah Medical Journal
Publisher : Universitas Hang Tuah

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30649/htmj.v23i1.662

Abstract

Background: Myelofibrosis with myeloid metaplasia is a rare myeloproliferative disorder. Epidemiological data on the incidence of Myelofibrosis with myeloid metaplasia are still lacking. In Goteborg, Sweden, from 1983 to 1992, the incidence of the disease was retrospectively calculated at 0.4 per 100,000 population. In population- based leukemia data in the UK, the incidence of Myelofibrosis with myeloid metaplasia is estimated to be 0.73 per 100,000 person-years in men and 0.40 per 100,000 person-years in women. It is estimated that there are 230 new cases each year in England and Wales, 330 in Italy, and 1,600 in the United States. No medical therapies have been shown to be effective against the overall survival of patients. The prognosis of myelofibrosis with myeloid metaplasia varies widely. For this reason, it is necessary to report cases of Myelofibrosis Myeloid Metaplasia Methode: Descriptive research, in the form of case reports of patients with myelofibrosis metaplasia, with data obtained from primary data anamnesa and direct physical examination of patients and secondary data from medical records, the results of examinations of doctors at RSPAL Dr Ramelan Surabaya 2022-2024. Results: Since 13 December 2022 until this date 3 May 2024 (17 months).Patient with a diagnosis of Primary Myelofibrosis and high Uric Acid after undergoing therapy with jakavi 15 mg 1x1. Allopurinol 300mg 1x1 and Nabic 3x1. Experienced improvement in complaints of increased appetite. Resting at night there are no complaints. Activity such as walking is not easily tired, mass in the abdomen that does not cause pain. On physical examination, there was an increase in body weight from 50 kg to 55 kg and still found S IV splenomegaly, from the haematological examination there was a decrease in platelets 136.00 (10^3µL) which was previously 203.00 (10^3µL). Uric acid improved from 10.8 mg/dl to 7.7 mg/dl. Conclusion: Jakavi is a drug containing ruxolitinib that can treat splenomegaly or disease-related symptoms in adult patients with myelofibrosis. Keywords: Myelofibrosis Metaplasia.Splenomegaly.Jakavi
Metaplasia Myelofibrosis WIJAYANINGRUM, LENA; I DEWA MADE WIDI HERSANA; I KETUT TIRKA NANDAKA
Hang Tuah Medical Journal Vol 23 No 1 (2025): Hang Tuah Medical Journal
Publisher : Universitas Hang Tuah

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30649/htmj.v23i1.662

Abstract

Background: Myelofibrosis with myeloid metaplasia is a rare myeloproliferative disorder. Epidemiological data on the incidence of Myelofibrosis with myeloid metaplasia are still lacking. In Goteborg, Sweden, from 1983 to 1992, the incidence of the disease was retrospectively calculated at 0.4 per 100,000 population. In population- based leukemia data in the UK, the incidence of Myelofibrosis with myeloid metaplasia is estimated to be 0.73 per 100,000 person-years in men and 0.40 per 100,000 person-years in women. It is estimated that there are 230 new cases each year in England and Wales, 330 in Italy, and 1,600 in the United States. No medical therapies have been shown to be effective against the overall survival of patients. The prognosis of myelofibrosis with myeloid metaplasia varies widely. For this reason, it is necessary to report cases of Myelofibrosis Myeloid Metaplasia Methode: Descriptive research, in the form of case reports of patients with myelofibrosis metaplasia, with data obtained from primary data anamnesa and direct physical examination of patients and secondary data from medical records, the results of examinations of doctors at RSPAL Dr Ramelan Surabaya 2022-2024. Results: Since 13 December 2022 until this date 3 May 2024 (17 months).Patient with a diagnosis of Primary Myelofibrosis and high Uric Acid after undergoing therapy with jakavi 15 mg 1x1. Allopurinol 300mg 1x1 and Nabic 3x1. Experienced improvement in complaints of increased appetite. Resting at night there are no complaints. Activity such as walking is not easily tired, mass in the abdomen that does not cause pain. On physical examination, there was an increase in body weight from 50 kg to 55 kg and still found S IV splenomegaly, from the haematological examination there was a decrease in platelets 136.00 (10^3µL) which was previously 203.00 (10^3µL). Uric acid improved from 10.8 mg/dl to 7.7 mg/dl. Conclusion: Jakavi is a drug containing ruxolitinib that can treat splenomegaly or disease-related symptoms in adult patients with myelofibrosis. Keywords: Myelofibrosis Metaplasia.Splenomegaly.Jakavi
Co-Authors Febrian, Amellia Ika I DEWA MADE WIDI HERSANA I KETUT TIRKA NANDAKA Jauhar, Tamam Tjahjono, Varidianto Yudo